ReviewImplementing TMB measurement in clinical practice: considerations on assay requirements
Cited by (0)
Contributors: All authors contributed to writing the manuscript and approved the final version.
Funding: Medical writing support and editorial assistance were provided by Stuart Rulten, PhD, and Jay Rathi, MA, of Spark Medica Inc, funded by Bristol-Myers Squibb, according to Good Publication Practice guidelines.
Competing interests: ER reports personal fees and non-financial support from AstraZeneca and Bristol-Myers Squibb. JL reports grants from Agilent Technologies and Roche Tissue Diagnostics, and personal fees from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Pfizer, and Roche Tissue Diagnostics. FL-R reports personal fees from AstraZeneca, Bristol-Myers Squibb, Life Technologies, Merck, Pfizer, and Roche. FP-L reports grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Merck, and Roche, and grants from NanoString. NN reports grants and personal fees from AstraZeneca, Bristol-Myers Squibb, Qiagen, Roche, and Thermo Fisher Scientific, and grants and non-financial support from Merck. SM-B reports grants and personal fees from AstraZeneca and Novartis, and personal fees from Bristol-Myers Squibb and Roche. RB declares no conflicts of interest.
Patient consent: Not required.
Provenance and peer review: Not commissioned; externally peer reviewed.